TY - JOUR
T1 - β-Naphthoflavone-Induced Mitochondrial Respiratory Damage in Cyp1 Knockout Mouse and in Cell Culture Systems
T2 - Attenuation by Resveratrol Treatment
AU - Anandasadagopan, Suresh Kumar
AU - Singh, Naveen M.
AU - Raza, Haider
AU - Bansal, Seema
AU - Selvaraj, Venkatesh
AU - Singh, Shilpee
AU - Chowdhury, Anindya Roy
AU - Leu, Nicolae Adrian
AU - Avadhani, Narayan G.
N1 - Funding Information:
The authors acknowledge the comments and suggestion of the Avadhani lab members. The authors also thank Dr. B. Kalyanaraman for generously providing the Mito-CP used in this work and Dr. Daniel W. Nebert for providing the transgenic mouse strains. The authors gratefully acknowledge the research support from NIH Grants R01 GM-034883 and R01-AA022986 and an endowment from the Harriet Ellison Woodward Trust to Narayan G. Avadhani.
Publisher Copyright:
© 2017 Suresh Kumar Anandasadagopan et al.
PY - 2017
Y1 - 2017
N2 - A number of xenobiotic-inducible cytochrome P450s (CYPs) are now known to be localized in the mitochondrial compartment, though their pharmacological or toxicological roles remain unclear. Here, we show that BNF treatment markedly inhibits liver mitochondrial O2 consumption rate (OCR), ADP-dependent OCR, and also reserve OCR, in wild-type mice but not in Cyp1a1/1a2(-/-) double knockout mice. BNF treatment markedly affected mitochondrial complex I and complex IV activities and also attenuated mitochondrial gene expression. Furthermore, under in vitro conditions, BNF treatment induced cellular ROS production, which was inhibited by mitochondria-targeted antioxidant Mito-CP and CYP inhibitor proadefin, suggesting that most of the ROS production was intramitochondrial and probably involved the catalytic activity of mitochondrial CYP1 enzymes. Interestingly, our results also show that the AHR antagonist resveratrol, markedly attenuated BNF-induced liver mitochondrial defects in wild-type mice, confirming the role of AHR and AHR-regulated CYP1 genes in eliciting mitochondrial dysfunction. These results are consistent with reduced BNF-induced mitochondrial toxicity in Cyp1a1/1a2(-/-) mice and elevated ROS production in COS cells stably expressing CYP1A1. We propose that increased mitochondrial ROS production and respiratory dysfunction are part of xenobiotic toxicity. Resveratrol, a chemopreventive agent, renders protection against BNF-induced toxicity.
AB - A number of xenobiotic-inducible cytochrome P450s (CYPs) are now known to be localized in the mitochondrial compartment, though their pharmacological or toxicological roles remain unclear. Here, we show that BNF treatment markedly inhibits liver mitochondrial O2 consumption rate (OCR), ADP-dependent OCR, and also reserve OCR, in wild-type mice but not in Cyp1a1/1a2(-/-) double knockout mice. BNF treatment markedly affected mitochondrial complex I and complex IV activities and also attenuated mitochondrial gene expression. Furthermore, under in vitro conditions, BNF treatment induced cellular ROS production, which was inhibited by mitochondria-targeted antioxidant Mito-CP and CYP inhibitor proadefin, suggesting that most of the ROS production was intramitochondrial and probably involved the catalytic activity of mitochondrial CYP1 enzymes. Interestingly, our results also show that the AHR antagonist resveratrol, markedly attenuated BNF-induced liver mitochondrial defects in wild-type mice, confirming the role of AHR and AHR-regulated CYP1 genes in eliciting mitochondrial dysfunction. These results are consistent with reduced BNF-induced mitochondrial toxicity in Cyp1a1/1a2(-/-) mice and elevated ROS production in COS cells stably expressing CYP1A1. We propose that increased mitochondrial ROS production and respiratory dysfunction are part of xenobiotic toxicity. Resveratrol, a chemopreventive agent, renders protection against BNF-induced toxicity.
UR - http://www.scopus.com/inward/record.url?scp=85030650134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030650134&partnerID=8YFLogxK
U2 - 10.1155/2017/5213186
DO - 10.1155/2017/5213186
M3 - Article
C2 - 29098061
AN - SCOPUS:85030650134
SN - 1942-0900
VL - 2017
JO - Oxidative medicine and cellular longevity
JF - Oxidative medicine and cellular longevity
M1 - 5213186
ER -